Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PCNA | P12004 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23729787 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL2119757 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRNAAARAB9AALDH1A1 | |
| SCHEMBL22296982 | 0.84 | NAAA (0.47) | TSHRHSD17B10NAAAALDH1A1CASP2 | |
| SCHEMBL5836462 | 0.82 | CNR1 (0.46) | SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL23342946 | 0.82 | MEN1 (0.42) | SMN1; SMN2TSHRNAAAALDH1A1CASP2 | |
| SCHEMBL13510958 | 0.81 | TSHR (0.50) | SMN1; SMN2TSHRNAAAALDH1A1EPHX2 | |
| SCHEMBL23711864 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRNAAARAB9AALDH1A1 | |
| SCHEMBL24943529 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL277913 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL16133369 | 0.81 | CASP2 (0.55) | SMN1; SMN2TSHRNAAACASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101670-B2 | Conjugates of an anti-TNF-α antibody | NEKTAR THERAPEUTICS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 2077/4885TSHR 1900/4885CASP1 1333/4885 |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | SMN1; SMN2 2811/4885TSHR 2225/4885CASP1 3783/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | SMN1; SMN2 1660/4885TSHR 2749/4885CASP1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.